Intravenous immunoglobulin therapy among pediatric patients: labeled and off-labeled indications
AUTOR(ES)
Toh, Chin Chiang, Islahudin, Farida, Ali, Adli, Shah, Noraida Mohamed
FONTE
Braz. J. Pharm. Sci.
DATA DE PUBLICAÇÃO
14/05/2018
RESUMO
ABSTRACT This study was designed to evaluate utilization patterns and clinical outcome of intravenous immunoglobulin (IVIG) therapy among pediatric patients in a tertiary hospital. Demographic data, IVIG prescribed, and clinical outcome were retrospectively reviewed from the pharmacy dispensing data and patient medical records between 2007 and 2014. One hundred and fifteen instances of IVIG administration to 108 pediatric patients were recorded. A total of 61 cases (53%) and 54 cases (47%) of the IVIG administered were for labeled and off-labeled indications, respectively. Age, weight, specialty, total IVIG usage, length of hospital stays, and mortality rate were found to be significantly associated with the indication being labeled or off-labeled (p<0.05). However, there was no significant difference in terms of adverse reactions between labeled and off-labeled indications (p>0.05). Guidelines should be developed and implemented for rational and evidence-based use of IVIG to avoid unnecessary wastage.
Documentos Relacionados
- One-year intravenous immunoglobulin replacement therapy: efficacy in reducing hospital admissions in pediatric patients with Inborn Errors of Immunity
- Indications for intravenous gammaglobulin therapy in inflammatory myopathies.
- Pellagra encephalopathy among tuberculous patients: its relation to isoniazid therapy.
- Intravenous immunoglobulin therapy in severe lupus myocarditis: good outcome in three patients
- NMO in pediatric patients: brain involvement and clinical expression